First-in-the-world approval is aimed at addressing the underlying causes of resistant high blood pressure.
The approval was supported by positive results from two Phase III clinical trials, BaxHTN and Bax24, which demonstrated statistically significant reductions in uncontrolled blood pressure when the treatment was used alongside standard therapies.
Fatima Al Kaabi said the decision reflects the UAE’s strategy to speed up access to advanced medical treatments through a flexible regulatory system.
Sameh El Fangary said the approval marks an important milestone in developing innovative hypertension therapies and highlights confidence in the scientific evidence behind the drug.
Hypertension remains one of the most common chronic conditions in the United Arab Emirates, affecting an estimated one in three adults despite the availability of multiple treatment options.
